New
HealthMore in Health→
Semaglutide shows antifibrotic signal in advanced MASH trial
Key Takeaways
- Large Phase 2 trial data suggest semaglutide may reduce fibrosis in advanced MASH.
- The benefit was reported without worsening liver inflammation.
- Patients with compensated cirrhosis were included, addressing a major unmet-need group.
- The semaglutide-zalfermin combination did not beat placebo.
DE
DT Editorial Team··via medicalxpress.com